CHHiP 试验基于医患报告结局推导直肠肛管剂量体积约束
CHHiP 试验将 3216 例局限期前列腺癌患者按 1:1:1 随机分配至 74 Gy/37 次、60 Gy/20 次和 57 Gy/19 次三种分割方案。本病例对照研究利用前瞻性收集的临床医生报告结局(CRO)和患者报告结局(PRO)推导直肠肛管剂量约束,并评估空间剂量指标的附加预测价值。
要点
- 仅 CRO 得出有统计学意义的剂量约束,PRO 未得出。
- 直肠出血主要与中高剂量相关,排便频繁、大便失禁和直肠疼痛主要与中等剂量相关。
- 空间剂量指标未改善对 CRO 或 PRO 的预测。
核心结论
- CRO 可推导出有统计学意义的直肠肛管剂量约束,PRO 未能推导出。
- 不同症状的剂量约束不同,提示放射性副作用的发病机制可能不同。
- 推导出的约束比 CHHiP 试验所用约束更严格,可能减少放疗后肠道症状。
研究设计与样本
- 病例对照研究,评估 7 项 CRO 和 5 项 PRO 肠道症状。
- 病例为放疗后 1 至 5 年出现中度或更重症状且放疗前无症状者,对照为基线和 1 至 5 年随访期间均无症状者。
- 直肠肛管从肛缘重新勾画至直肠乙状结肠交界处并提取剂量体积参数。
- 采用单因素逻辑回归、并发症指数图谱和自助法受试者工作特征分析(1000 次重复,结局平衡)推导约束。
- 全队列分析时大分割方案按 α/β=3 Gy 转换为 2 Gy 等效方案。
主要发现
- 仅 CRO 得出有统计学意义的剂量约束,PRO 未得出。
- 直肠出血与中高剂量相关,排便频繁、大便失禁和直肠疼痛与中等剂量相关。
- 空间剂量指标未改善对 CRO 或 PRO 的预测。
- 仅曲线下面积 95% 置信区间下限 >0.5 被视为有统计学意义。
- 在少于 95% 至 99% 自助样本中出现的约束被排除。
关键数值与推荐
- 大分割方案(60 Gy 或 57 Gy)新剂量约束:V20Gy<85%、V30Gy<57%、V40Gy<38%、V50Gy<22%、V60Gy<0.01%。
- 该约束比 CHHiP 试验所用约束更严格。
临床怎么用
- 可将推导出的直肠肛管剂量约束用于大分割前列腺癌放疗计划评估,以可能减少放疗后肠道症状。
- 对直肠出血应关注中高剂量,对排便频繁、大便失禁和直肠疼痛应关注中等剂量。
- 空间剂量指标目前不推荐用于改善症状预测。
局限性
- PRO 未推导出有统计学意义的剂量约束。
- 空间剂量指标未改善预测。
- 约束推导基于自助法稳定性筛选,部分候选约束被排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The CHHiP trial randomized 3216 men with localized prostate cancer (1:1:1) to 3 radiation therapy fractionation schedules: 74 Gy in 37 fractions over 7.4 weeks; 60 Gy in 20 fractions over 4 weeks; and 57 Gy in 19 fractions over 3.8 weeks. Literature-based dose constraints were applied with arithmetic adjustment for the hypofractionated arms. This study aimed to derive anorectal dose constraints using prospectively collected clinician-reported outcomes (CROs) and patient-reported outcomes (PROs) and to assess the added predictive value of spatial dose metrics. METHODS AND MATERIALS: A case-control study design was used; 7 CRO and 5 PRO bowel symptoms were evaluated. Cases experienced a moderate or worse symptom 1 to 5 years after-radiation therapy and did not have the symptom before radiation therapy. Controls did not experience the symptom at baseline or between 1 to 5 years after radiation therapy. The anorectum was recontoured from the anal verge to the rectosigmoid junction; dose/volume parameters were extracted. Univariate logistic regression, atlases of complication indices, and bootstrapped receiver-operating-characteristic analysis (1000 replicates, balanced outcomes) were used to derive dose constraints for the whole cohort (hypofractionated schedules were converted to 2-Gy equivalent schedules using α/β = 3 Gy) and separate hypofractionated/conventional fractionation cohorts. Only areas under the curve with 95% confidence interval lower limits >0.5 were considered statistically significant. Any constraint derived in <95% to 99% of bootstraps was excluded. RESULTS: Statistically significant dose constraints were derived for CROs but not PROs. Intermediate to high doses were important for rectal bleeding, whereas intermediate doses were important for increased bowel frequency, fecal incontinence, and rectal pain. Spatial dose metrics did not improve prediction of CROs or PROs. A new panel of dose constraints for hypofractionated schedules to 60 Gy or 57 Gy are V20Gy <85%, V30Gy <57%, V40Gy <38%, V50Gy <22%, and V60Gy <0.01%. CONCLUSIONS: Dose constraints differed among symptoms, indicating potentially different pathogenesis of radiation-induced side effects. Derived dose constraints were stricter than those used in CHHiP and may reduce bowel symptoms after radiation therapy.
引用
- Wilkins A, Naismith O, Brand D, et al. Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation. Int J Radiat Oncol Biol Phys. 2020. PMID: 31987974. doi:10.1016/j.ijrobp.2020.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。